EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496

被引：0

作者：

Evens, A. M. ^{[1
]}

Hong, F. ^{[2
]}

Gordon, L. I. ^{[3
]}

Fisher, R. I. ^{[4
]}

Bartlett, N. ^{[5
]}

Connors, J. M. ^{[6
]}

Wagner, H. ^{[7
]}

Gospodarowicz, M. ^{[8
]}

Cheson, B. D. ^{[9
]}

Advani, R. ^{[10
]}

Kahl, B. S. ^{[11
]}

Hoppe, R. T. ^{[10
]}

Horning, S. J. ^{[12
]}

机构：

[1] Univ Massachusetts, Worcester, MA 01605 USA

[2] Harvard Univ, ECOG Stat Ctr, Boston, MA 02115 USA

[3] Northwestern Univ, Chicago, IL 60611 USA

[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14627 USA

[5] Washington Univ, St Louis, MO USA

[6] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[7] Penn State Canc Inst, Hershey, PA USA

[8] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[9] Georgetown Univ Hosp, Washington, DC 20007 USA

[10] Stanford Univ, Stanford, CA 94305 USA

[11] Univ Wisconsin, Madison, WI 53706 USA

[12] Genentech Inc, Clin Dev, San Francisco, CA 94080 USA

来源：

ANNALS OF ONCOLOGY | 2011年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：117 / 118

页数：2

共 35 条

[1] Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496
Evens, A. M.
Hong, F.
Gordon, L. I.
Fisher, R. I.
Bartlett, N.
Connors, J. M.
Wagner, H.
Gospodarowicz, M. K.
Cheson, B. D.
Advani, R.
Kahl, B. S.
Hoppe, R. T.
Horning, S. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
Gordon, Leo I.
Hong, Fangxin
Fisher, Richard I.
Bartlett, Nancy L.
Connors, Joseph M.
Gascoyne, Randy D.
Wagner, Henry
Stiff, Patrick J.
Cheson, Bruce D.
Gospodarowicz, Mary
Advani, Ranjana
Kahl, Brad S.
Friedberg, Jonathan W.
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph M.
Hoppe, Richard T.
Horning, Sandra J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 684 - 691
[3] Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496
Advani, Ranjana
Hong, Fangxin
Fisher, Richard I.
Bartlett, Nancy L.
Robinson, Sue
Gascoyne, Randy D.
Wagner, Henry
Stiff, Patrick J.
Cheson, Bruce D.
Stewart, Douglas A.
Gordon, Leo I.
Kahl, Brad
Friedberg, Jonathan W.
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph
Hoppe, Richard
Horning, Sandra J.
BLOOD, 2010, 116 (21) : 185 - 186
[4] Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496
Advani, Ranjana
Hong, Fangxin
Gordon, Leo I.
Gascoyne, Randy D.
Wagner, Henry
Hoppe, Richard T.
Fisher, Richard I.
Bartlett, Nancy L.
Kahl, Brad S.
Stiff, Patrick
Cheson, Bruce D.
Belch, Andrew R.
Friedberg, Jonathan W.
Kassis, Jeannine
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph
Horning, Sandra J.
BLOOD, 2011, 118 (21) : 696 - 697
[5] A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)
Gordon, Leo I.
Hong, Fanxing
Fisher, Richard I.
Bartlett, Nancy L.
Connors, Joseph M.
Gascoyne, Randy D.
Wagner, Henry
Stiff, Patrick J.
Cheson, Bruce D.
Gospodarowicz, Mary
Advani, Ranjana
Kahl, Brad
Friedberg, Jonathan W.
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph
Hoppe, Richard
Horning, Sandra J.
BLOOD, 2010, 116 (21) : 185 - 185
[6] The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
Evens, Andrew M.
Hong, Fangxin
Gordon, Leo I.
Fisher, Richard I.
Bartlett, Nancy L.
Connors, Joseph M.
Gascoyne, Randy D.
Wagner, Henry
Gospodarowicz, Mary
Cheson, Bruce D.
Stiff, Patrick J.
Advani, Ranjana
Miller, Thomas P.
Hoppe, Richard T.
Kahl, Brad S.
Horning, Sandra J.
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 76 - 86
[7] Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
Advani, Ranjana H.
Hong, Fangxin
Fisher, Richard I.
Bartlett, Nancy L.
Robinson, K. Sue
Gascoyne, Randy D.
Wagner, Henry, Jr.
Stiff, Patrick J.
Cheson, Bruce D.
Stewart, Douglas A.
Gordon, Leo I.
Kahl, Brad S.
Friedberg, Jonathan W.
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph M.
Hoppe, Richard T.
Horning, Sandra J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1936 - U111
[8] Tumor-Associated Macrophages Predict Inferior Outcomes in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma - A Correlative Study from the E2496 Intergroup Trial
Tan, K. L.
Scott, D. W.
Hong, F.
Horning, S. J.
Fisher, R. I.
Bartlett, N. L.
Shepherd, L. E.
Connors, J. M.
Kahl, B. S.
Gordon, L. I.
Steidl, C.
Gascoyne, R. D.
MODERN PATHOLOGY, 2012, 25 : 374A - 375A
[9] Tumor-Associated Macrophages Predict Inferior Outcomes in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma - A Correlative Study from the E2496 Intergroup Trial
Tan, K. L.
Scott, D. W.
Hong, F.
Horning, S. J.
Fisher, R. I.
Bartlett, N. L.
Shepherd, L. E.
Connors, J. M.
Kahl, B. S.
Gordon, L. I.
Steidl, C.
Gascoyne, R. D.
LABORATORY INVESTIGATION, 2012, 92 : 374A - 375A
[10] Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): Results of a UKNCRI/LTO randomised phase II trial.
Johnson, P
Hoskin, P
Horwich, A
Hancock, B
Smith, P
Stevens, L
Qian, W
Sweetenham, JW
BLOOD, 2004, 104 (11) : 93A - 93A

← 1 2 3 4 →